Group items matching

in title, tags, annotations or url

The FY19 PRCRP Translational Team Science Award (TTSA) supports hypothesis-driven translational studies. These studies should be associated with a clinical trial. The proposed project should focus on research for the next-phase clinical trial or future clinical application. The TTSA is intended to support advanced translational studies that are based on results from clinical investigations. While funding for clinical trials is allowed, the TTSA is intended to support multi-investigator, multidisciplinary teams to perform clinical research studies and not only to fund a clinical trial. Research projects funded by the TTSA should address critical knowledge gaps in clinical outcomes, validate key research results, expand upon potentially game-changing results, or investigate novel clinical findings. New for FY19: The FY19 PRCRP TTSA Areas of Emphasis (strongly encouraged but not required): · Interventions to improve quality of life for cancer patients and/or survivors · Cancer prevention or early detection · Understanding metastatic disease to improve outcomes

The American Association for Cancer Research is accepting applications for its AACR NextGen Grants for Transformative Cancer Research program. The annual program is designed to stimulate highly innovative research from young investigators. Three-year grants of up to $450,000 will be awarded in support of creative, paradigm-shifting cancer research that might not be funded through conventional channels. The funds are intended to support expenses related to the research project, which may include salary and benefits of the grant recipient, postdoctoral or clinical research fellows, graduate students (including tuition costs), and research assistants; research/laboratory supplies and equipment; travel applicable to the research project; publication charges for manuscripts that pertain directly to the funded project; and other research expenses and indirect costs. Research projects must represent a highly innovative approach to a major contemporary challenge in cancer research. The research, which can be in any area of basic, translational or clinical science, must have the potential to lead to groundbreaking discoveries in the field and transform our understanding of the tumorigenesis process and/or ability to treat, detect, or prevent cancer. To be eligible, applicants must have a doctoral degree in a related field and not currently be a candidate for a further doctoral degree. In addition, at the start of the grant term on July 1, 2018, applicants must hold a tenure-eligible appointment at the level of assistant professor; have held this appointment for no more than three years; and work at an academic, medical, or research institution anywhere in the world. AACR membership is required.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. This purpose of this FOA is to promote research in colorectal cancer (CRC) screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based approaches. The Accelerating Colorectal Cancer Screening and Follow-up through Implementation Science (ACCSIS) program will provide an evidence base for multilevel interventions that increase rates of CRC screening, follow-up, and referral-to-care, and best practices for how multilevel interventions can be scaled-up to reduce the burden of colorectal cancer on the United States (U.S.) population. The UG3/UH3 projects in response to this FOA must apply for both the UG3 and UH3 phases together in the single application. The UG3 effort is to be used for the development of one-year, milestone-driven planning phase (UG3), with possible rapid transition to the second phase (UH3) for clinical trials. UH3s will be awarded after administrative review of eligible UG3s that have met the scientific milestones and feasibility requirements necessary for the UH3 phase, depending on availability of funds.

The purpose of the U.S.-Russia Bilateral Collaborative Research Partnerships on Cancer program is to stimulate collaborative basic, translational, and clinical research between United States (U.S.)-based researchers and Russian researchers in the areas of cancer biology, prevention, early detection, diagnosis, and treatment as well as the physical and chemical sciences and engineering in cancer biology, nanotechnology, and radiation epidemiology.

The purpose of the U.S.-Russia Bilateral Collaborative Research Partnerships on Cancer program is to stimulate collaborative basic, translational, and clinical research between United States (U.S.)-based researchers and Russian researchers in the areas of cancer biology, prevention, early detection, diagnosis, and treatment as well as the physical and chemical sciences and engineering in cancer biology, nanotechnology, and radiation epidemiology.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish Centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish Centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.

The International Foundation for Ethical Research (IFER) is pleased to call for pre-proposal applications for its 2013 Graduate Student Fellowships for Alternatives to the Use of Animals in Science. The fellowships provide up to $12,500 annually in stipendiary support and up to $2,500 for supplies per year. The fellowships are renewable annually for up to three years. Continued funding is dependent on student progress and availability of funds.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications for projects that bridge biological mechanism to population level scales. By incorporating insights and data from one end of the cancer research spectrum into the framework of the other, projects should be able to cross-validate data gathered at different scales, and explore links between basic biology, population science, and potential health applications in treatment, prevention, diagnosis, and/or screening. Proposed projects should pose a challenging cancer research question that can be addressed by connecting these two ends of the research spectrum that would be difficult to address or explain through biological or epidemiological investigation alone. Only a single cohesive project integrating aspects from these two areas is allowed in each application.

The Alfred P. Sloan Foundation makes grants on six broad subject matters, known within the Foundation as major program areas.  Basic Research STEM Higher Education Public Understanding of Science Economic Performance and the Quality of Life Select National Issues Civic Initiatives

The OCRP Teal Innovator Award supports a visionary individual from any field principally outside of, but not exclusive of, ovarian cancer to focus his/her creativity, innovation, and leadership on ovarian cancer research. The Teal Innovator Award will provide the Principal Investigator (PI) with the funding and freedom to pursue his/her most novel, visionary, high-risk ideas that could significantly impact the field of ovarian cancer research or patient care. The proposed Teal Innovator must be highly recognized in his/her field and present evidence of this recognition. Examples include, but are not limited to, recognition at the level of endowed chair; membership in the National Academy of Sciences, National Academy of Engineering, or Institute of Medicine; Chairmanship of the American Association for Cancer Research; or other national or international recognition.

The purpose of this funding opportunity is to establish a program of research to advance the understanding, prevention and treatment of pediatric multiple organ dysfunction syndrome (MODS). Given the prevalence and associated morbidity and mortality of MODS in children, the current lack of understanding underscores the need for more exploratory research. Possible topics of study include, but are not limited to, the epidemiology, pathophysiology, monitoring, and treatment of MODS. Studies that assess specific etiologies associated with MODS including, but not limited to, sepsis, trauma, acute respiratory distress syndrome, inborn errors of metabolism, burns, cancer, transplantation and congenital heart disease are encouraged. Applications may include any appropriate study design ranging from basic science animal models through small prospective randomized controlled trials. The intent of this R21 funding initiative is to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of research projects addressing these topics. These studies may incur considerable research risk in efforts to make important breakthroughs in the understanding, prevention and treatment of MODS in children. Projects of limited cost or scope that use widely accepted approaches and methods within well-established fields are better suited for the R03 small grant activity code. It is hoped that the results of this exploratory research will translate into improved clinical outcomes for children with, and at risk for MODS.

The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical or population science cancer research program, but not serve as independent investigators. These scientists, such as researchers within a research program, are vital to sustaining the biomedical research enterprise. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others for career continuity.    

I-Corps@Ohio is a statewide program to assist faculty and graduate students from Ohio universities and colleges to validate the market potential of their technologies and validate and launch startup companies. I-Corps@Ohio is modeled after the National Science Foundation's (NSF) successful I-Corps program, which is proven to increase innovation, entrepreneurship, and industry collaboration. The I-Corps@Ohio program is an initiative of the Ohio Department of Higher Education.

The AACR-Women in Cancer Research Charlotte Friend Memorial Lectureship was established in 1998 in honor of renowned virologist and discoverer of the Friend virus, Dr. Charlotte Friend, for her pioneering research on viruses, cell differentiation and cancer. The lecture is intended to give recognition to an outstanding female or male scientist who has made meritorious contributions to the field of cancer research and who has, through leadership or by example, furthered the advancement of women in science.

The American Association for Cancer Research established this award in 2007 in honor of Margaret Foti, Ph.D., M.D. (h.c.), for her exemplary leadership of the AACR as its chief executive officer; for her sustained, outstanding work in fostering research, scholarly communications, education and training, science policy and public education; and for her extraordinary dedication and contributions to the conquest of cancer. This award recognizes a true champion of cancer research, an individual who embodies the sustained commitment of Margaret Foti to the prevention and cure of cancer. The award is given to an individual whose leadership and extraordinary achievements in cancer research or in support of cancer research have made a major impact on the field. Such achievements include contributions to the acceleration of progress in cancer research, raising national or international awareness of cancer research, or other demonstrations of a sustained commitment to the conquest of cancer.

The Pancreatic Cancer Action Network-AACR Innovative Grants represent a joint effort to promote and support innovative pancreatic cancer research. They aim to spur creative and cutting-edge ideas and approaches in pancreatic cancer research, including those successful in other areas of cancer that have justifiable promise for pancreatic cancer. The research proposed for funding may be basic, translational, clinical or epidemiological in nature and must have direct applicability and relevance to pancreatic cancer. These grants are available to full time, independent junior and senior investigators, including those with experience in other areas of cancer or biomedical/health science research who have promising ideas and approaches that can be applied to pancreatic cancer research. The grants provide $200,000 over two years ($100,000 per year) for direct and indirect expenses related to the research project, which may include salary and benefits of the grant recipient and any collaborators (grant recipient/collaborator salaries limited to 20 percent of the total grant), postdoctoral or clinical research fellows, graduate students and/or research assistants, research/laboratory supplies, equipment and publication charges for manuscripts that pertain directly to the funded project. It is anticipated that multiple Innovative Grants will be funded.

The Pancreatic Cancer Action Network-AACR Innovative Grants represent a joint effort to promote and support innovative pancreatic cancer research. They aim to spur creative and cutting-edge ideas and approaches in pancreatic cancer research, including those successful in other areas of cancer that have justifiable promise for pancreatic cancer. The research proposed for funding may be basic, translational, clinical or epidemiological in nature and must have direct applicability and relevance to pancreatic cancer. These grants are available to full time, independent junior and senior investigators, including those with experience in other areas of cancer or biomedical/health science research who have promising ideas and approaches that can be applied to pancreatic cancer research.

This Funding Opportunity Announcement (FOA) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPOREs). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer (or a related group of cancers). SPOREs are expected not only to conduct a wide spectrum of research activities, but also to contribute significantly to the development of specialized shared resources Core facilities (Cores), improved research model systems, and collaborative research projects with other institutions. The research supported through this program must be translational in nature and must always be focused upon knowledge of human biology stemming from research using cellular, molecular, structural, biochemical, and/or genetic experimental approaches with the goal of a translational human endpoint within the project period of the grant. In addition, SPOREs must include both a Developmental Research Program for pilot studies and a Career Development Program to foster careers in organ-based translational science.

The Kure It-AACR Grant for Kidney Cancer Research represents a joint effort to promote and support innovative cancer research. This grant is available to full time, independent junior and senior investigators to develop and study new ideas and innovative approaches that have direct application and relevance to kidney cancer patients. Applicants with experience in other areas of cancer or biomedical/health science research who have promising ideas and approaches that can be applied to kidney cancer research are encouraged to apply.

The Lung Cancer Research Foundation supports research on innovative strategies for better treatments, screening, and prevention of all cancers of the lung. The foundation's goal is to fund promising scientific and clinical research initiatives that lead to more positive outcomes and improved quality of life for all lung cancer patients.   To that end, LCRF has issued a Request for Proposals designed to provide critical seed support for cutting-edge scientific research on all lung cancers. Through its Research Grant program, the foundation will support projects with a focus on basic science, translational research, clinical research, supportive care, and quality of care/outcomes.   Grants of up to $75,000 will be awarded.   The program is open to all U.S. and international investigators, including graduate students, postdoctoral researchers, physicians, medical students, and nurse researchers.